Hill, Andrew

Dolutegravir plus two different prodrugs of tenofovir to treat HIV

Venter, W. D. F., Moorhouse, M., Sokhela, S., Fairlie, L., Mashabane, N., Masenya, M., Serenata, C., Akpomiemie, G., Qavi, A., Chandiwana, N., et al. (2019) · New England Journal of Medicine

HIV/AIDS drug development and treatmentHIV/AIDS Research and Interventions

Cited by 723

Implications of weight gain with newer anti-retrovirals: 10-year predictions of cardiovascular disease and diabetes

McCann, K., Shah, S., Hindley, L., Hill, A., Qavi, A., Simmons, B., Serenata, C., Sokhela, S., & Venter, W. D. F. (2021) · AIDS

HIV-related health complications and treatmentsHIV/AIDS drug development and treatment

Cited by 72

Estimated minimum prices and lowest available national prices for antiobesity medications: Improving affordability and access to treatment

Levi, J., Wang, J., Venter, F., & Hill, A. (2023) · Obesity

Pharmaceutical Economics and PolicyPharmacology and Obesity Treatment

Cited by 69

Hepatitis C can be cured globally, but at what cost?

Hill, A., & Cooke, G. (2014) · Science

Hepatitis C virus researchPharmaceutical Economics and Policy

Cited by 65

Ivermectin for COVID-19: Addressing Potential Bias and Medical Fraud

Hill, A., Mirchandani, M., & Pilkington, V. (2022) · Open Forum Infectious Diseases

COVID-19 Clinical Research StudiesMeta-analysis and systematic reviews

Cited by 57